BeOne Medicines Ltd ADR’s recently made public that its Officer XIAOBIN WU acquired Company’s shares for reported $1.52 million on Nov 17 ’25. In the deal valued at $380.43 per share,3,991 shares were bought.
Then, Wu Xiaobin sold 10,000 shares, generating $3,560,161 in total proceeds. Upon selling the shares at $356.02, the President and COO now owns 6,009 shares.
Before that, Wu Xiaobin sold 6,009 shares. BeOne Medicines Ltd ADR shares valued at $2,286,660 were divested by the President and COO at a price of $380.54 per share. As a result of the transaction, Wu Xiaobin now holds 0 shares, worth roughly $0.0.
Barclays initiated its BeOne Medicines Ltd ADR [ONC] rating to an Overweight in a research note published on September 18, 2025; the price target was $385. A number of analysts have revised their coverage, including RBC Capital Mkts’s analysts, who began to cover the stock in early April with a ‘”an Outperform”‘ rating. BofA Securities also remained covering ONC and has increased its forecast on March 03, 2025 with a “Buy” recommendation from previously “Neutral” rating.
Price Performance Review of ONC
On Monday, BeOne Medicines Ltd ADR [NASDAQ:ONC] saw its stock jump 2.96% to $376.63. Over the last five days, the stock has gained 14.41%. BeOne Medicines Ltd ADR shares have risen nearly 92.70% since the year began. Nevertheless, the stocks have risen 103.90% over the past one year. While a 52-week high of $381.50 was reached on 11/17/25, a 52-week low of $170.99 was recorded on 01/08/25.
Levels Of Support And Resistance For ONC Stock
The 24-hour chart illustrates a support level at 371.56, which if violated will result in even more drops to 366.49. On the upside, there is a resistance level at 383.46. A further resistance level may holdings at 390.29.
How much short interest is there in BeOne Medicines Ltd ADR?
A steep rise in short interest was recorded in BeOne Medicines Ltd ADR stocks on 2025-10-31, growing by 0.24 million shares to a total of 1.57 million shares. Yahoo Finance data shows the prior-month short interest on 2025-09-30 was 1.32 million shares. There was a rise of 15.45%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on September 18, 2024 when JMP Securities began covering the stock and recommended ‘”a Mkt outperform”‘ rating along with a $288 price target.
